Immatics N.V. IMTX
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Immatics N.V. (IMTX) is a healthcare company listed in the US with a market value of about $956M. In the twelve months to September 30, 2026 it had revenue of $48M and net income of -$252M, a net margin of -526.6%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -87%.
About Immatics
Immatics is listed in the US and classified in biotechnology: biological products (no diagnostic substances). It was profitable in 2 of the last 8 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48M | — | — | — | — | — | — | — | — |
| Net income | -$252M | -$231M | $16M | -$105M | $30M | -$106M | -$259M | -$35M | -$36M |
| Free cash flow | -$248M | -$215M | -$181M | -$14M | $101M | -$102M | -$108M | $77M | $23M |
| EPS (diluted) | $-1.87 | $-1.54 | $0.11 | $-0.70 | $0.20 | $-0.71 | $-1.73 | $-0.24 | $-0.24 |
| Net margin | -526.6% | — | — | — | — | — | — | — | — |
| ROIC | — | -37.2% | -4.8% | -45.6% | 9.7% | -358.6% | -79.8% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Immatics pay a dividend?
Not currently.
Is Immatics a good stock to buy?
We do not give buy or sell advice. Immatics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.